$ADVM
Adverum Biotechnologies, Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016028352 Filed on November 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $488.0K $395.0K $953.0K
YoY Change -49.17% -58.55% 367.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.780M $6.150M $7.630M
YoY Change -10.99% -19.4% 217.92%
% of Gross Profit
Research & Development $7.900M $8.360M $7.523M
YoY Change -4.13% 11.13% 30.93%
% of Gross Profit
Depreciation & Amortization $480.0K $460.0K $240.0K
YoY Change 60.0% 91.67% 380.0%
% of Gross Profit
Operating Expenses $23.88M $14.90M $15.15M
YoY Change 57.71% -1.66% 86.08%
Operating Profit -$14.20M
YoY Change 78.85%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $220.0K $210.0K $117.0K
YoY Change 144.44% 79.49% -137.03%
Pretax Income -$23.17M -$14.30M -$14.08M
YoY Change 64.44% 1.56% 70.46%
Income Tax -$780.0K
% Of Pretax Income
Net Earnings -$22.39M -$14.30M -$14.08M
YoY Change 58.89% 1.54% 70.59%
Net Earnings / Revenue -4588.93% -3620.51% -1477.86%
Basic Earnings Per Share
Diluted Earnings Per Share -$535.1K -$345.2K -$548.1K
COMMON SHARES
Basic Shares Outstanding 41.72M 25.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $222.2M $231.3M $268.9M
YoY Change -14.24% -13.98% 62.67%
Cash & Equivalents $222.2M $231.3M $200.7M
Short-Term Investments $68.20M
Other Short-Term Assets $2.200M $2.800M $1.500M
YoY Change 46.67% 86.67% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $225.3M $235.9M $270.4M
YoY Change -13.69% -12.75% 62.54%
LONG-TERM ASSETS
Property, Plant & Equipment $4.169M $4.300M $3.330M
YoY Change 30.81% 29.13% 307.59%
Goodwill
YoY Change
Intangibles $5.000M
YoY Change
Long-Term Investments
YoY Change
Other Assets $140.0K $140.0K $138.0K
YoY Change 0.0% 1.45% 55.06%
Total Long-Term Assets $9.309M $20.70M $3.468M
YoY Change 179.8% 496.89% 282.78%
TOTAL ASSETS
Total Short-Term Assets $225.3M $235.9M $270.4M
Total Long-Term Assets $9.309M $20.70M $3.468M
Total Assets $234.6M $256.6M $273.8M
YoY Change -11.25% -6.29% 63.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.474M $3.100M $1.141M
YoY Change 143.64% 171.69% -29.87%
Accrued Expenses $6.500M $5.800M $3.700M
YoY Change 62.5% 56.76% 85.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.896M $10.60M $6.496M
YoY Change 50.53% 63.18% 45.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $386.0K $7.700M $5.000M
YoY Change -92.58% 54.0% -28.57%
Total Long-Term Liabilities $386.0K $7.700M $5.000M
YoY Change -92.58% 54.0% -28.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.896M $10.60M $6.496M
Total Long-Term Liabilities $386.0K $7.700M $5.000M
Total Liabilities $18.98M $20.30M $11.50M
YoY Change 61.87% 76.54% -0.04%
SHAREHOLDERS EQUITY
Retained Earnings -$197.9M -$70.07M
YoY Change 135.14% 166.2%
Common Stock $413.5M $332.4M
YoY Change 22.79% 16620250.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $215.6M $236.2M $262.3M
YoY Change
Total Liabilities & Shareholders Equity $234.6M $256.6M $273.8M
YoY Change -11.25% -6.29% 63.74%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$22.39M -$14.30M -$14.08M
YoY Change 58.89% 1.54% 70.59%
Depreciation, Depletion And Amortization $480.0K $460.0K $240.0K
YoY Change 60.0% 91.67% 380.0%
Cash From Operating Activities -$8.350M -$9.640M -$9.220M
YoY Change -8.54% 4.56% 85.51%
INVESTING ACTIVITIES
Capital Expenditures -$920.0K -$360.0K -$1.310M
YoY Change 384.21% -72.52% 1090.91%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $10.64M
YoY Change -100.0% -100.0%
Cash From Investing Activities -$920.0K -$360.0K $9.320M
YoY Change -103.06% -103.86% -8572.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 210.0K 0.000 50.00K
YoY Change -175.0% -100.0% -99.96%
NET CHANGE
Cash From Operating Activities -8.350M -9.640M -9.220M
Cash From Investing Activities -920.0K -360.0K 9.320M
Cash From Financing Activities 210.0K 0.000 50.00K
Net Change In Cash -9.060M -10.00M 150.0K
YoY Change -143.87% -6766.67% -99.87%
FREE CASH FLOW
Cash From Operating Activities -$8.350M -$9.640M -$9.220M
Capital Expenditures -$920.0K -$360.0K -$1.310M
Free Cash Flow -$7.430M -$9.280M -$7.910M
YoY Change -16.89% 17.32% 62.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3187000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
66000
CY2016Q3 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5777000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1463000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
260992000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91366000
us-gaap Share Based Compensation
ShareBasedCompensation
9852000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
532000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-988000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1359000
us-gaap Straight Line Rent
StraightLineRent
-218000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26212000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19600000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2804000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-71631000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
633000
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41718515
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221348000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
37732000
CY2015Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
449000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
883000
CY2016Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2025000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
24000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-570000
advm Increase Decrease In Deposit And Other Noncurrent Assets
IncreaseDecreaseInDepositAndOtherNoncurrentAssets
1000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2936000
us-gaap Straight Line Rent
StraightLineRent
47000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-30024000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
88427000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3449000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
39699000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
138954000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
493000
advm Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
113000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
100000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
353000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
139135000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-105000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-20000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9923000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41272000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159404000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
447000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4706000
CY2015Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4007000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1116000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
817000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25685000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-46000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1317000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
542000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6574000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33372000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25378000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2016Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
25000
CY2015Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
2000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.66
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34382000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
506000
us-gaap Share Based Compensation
ShareBasedCompensation
7084000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
283000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
388000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
37738000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1488000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200676000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
64845000
advm Fixed Assets In Accounts Payable Accrued Expenses And Other Current Liabilities
FixedAssetsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities
771000
advm Fixed Assets In Accounts Payable Accrued Expenses And Other Current Liabilities
FixedAssetsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities
182000
CY2015Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
1
us-gaap Maturities Of Time Deposits Description
MaturitiesOfTimeDepositsDescription
Less than one year
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
225735000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
246320000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6442000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4178000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2107000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
991000
CY2016Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
453000
CY2015Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
241000
CY2016Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2364000
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2015Q4 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
208588000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
37738000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
dei Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
2016-05-11
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2369375
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
130600000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8300000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
230000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q3 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0
CY2015Q4 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
208588000
CY2015Q4 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2047000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
941000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1177000
CY2016Q3 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
1992000
CY2015Q4 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
642000
CY2016Q3 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
430000
CY2015Q4 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
101000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2016Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
advm Share Based Compensation Arrangement By Share Based Payment Award Options Difference Between Options Exercise Price And Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDifferenceBetweenOptionsExercisePriceAndClosingPriceOfCommonStockIntrinsicValueAmount
4.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.27
CY2015Q3 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
5752000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11200000
CY2016Q3 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
2942000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.92
advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
9852000
advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
7084000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
4
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
4
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.81
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2016Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2015Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5800000

Files In Submission

Name View Source Status
0001564590-16-028352-index-headers.html Edgar Link pending
0001564590-16-028352-index.html Edgar Link pending
0001564590-16-028352.txt Edgar Link pending
0001564590-16-028352-xbrl.zip Edgar Link pending
advm-10q_20160930.htm Edgar Link pending
advm-20160930.xml Edgar Link completed
advm-20160930.xsd Edgar Link pending
advm-20160930_cal.xml Edgar Link unprocessable
advm-20160930_def.xml Edgar Link unprocessable
advm-20160930_lab.xml Edgar Link unprocessable
advm-20160930_pre.xml Edgar Link unprocessable
advm-ex101_307.htm Edgar Link pending
advm-ex311_10.htm Edgar Link pending
advm-ex312_12.htm Edgar Link pending
advm-ex321_13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending